Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib ± pembrolizumab vs standard of care in FGFR3+ urothelial carcinoma
NCT04003610Phase 2Terminated
- Sponsor
- Incyte
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 16
01
Overview
Phase 2, randomised, open-label trial of pemigatinib in urothelial carcinoma (UC) (3 arms), sponsored by Incyte. Primary endpoint: Progression-Free Survival at 130 days. Started May 2020; status: terminated.
02
Drugs
pemigatinib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04003610.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04003610.